tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Idorsia Ltd (CH:IDIA)
:IDIA
Switzerland Market
IDIA
Idorsia Ltd
RESEARCH TOOLSreports

Idorsia Ltd (IDIA) Stock News & Sentiment

Compare
13 Followers
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
Premium
Ratings
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
4d ago
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
Premium
Ratings
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
9d ago
Idorsia Earnings Call Signals Turnaround, Risks Linger
Premium
Company Announcements
Idorsia Earnings Call Signals Turnaround, Risks Linger
24d ago
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
Premium
Ratings
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
1M ago
Idorsia: Latin America QUVIVIQ Deal and Pipeline Optionality De‑Risk Path to Profitability, Supporting Reiterated Buy Rating
Premium
Ratings
Idorsia: Latin America QUVIVIQ Deal and Pipeline Optionality De‑Risk Path to Profitability, Supporting Reiterated Buy Rating
2M ago
Idorsia: Differentiated Insomnia and Hypertension Assets, Understated Guidance, and Pipeline Upside Support Reiterated Buy Rating
Premium
Ratings
Idorsia: Differentiated Insomnia and Hypertension Assets, Understated Guidance, and Pipeline Upside Support Reiterated Buy Rating
2M ago
Premium
Ratings
Idorsia: Cardiovascular Franchise Momentum and Underappreciated Pipeline Drive Buy Rating and Valuation Upside
3M ago
More CH:IDIA News >

IDIA News on the Web

Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
TipRanks News
Bullish
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
TipRanks News
Bullish
Idorsia price target lowered to CHF 5 from CHF 6 at H.C. Wainwright
TipRanks News
Neutral
Kepler Capital Sticks to Their Buy Rating for Idorsia Ltd (IDIA)
TipRanks News
Bullish
Idorsia Ltd (IDRSF) Full Year 2025 Earnings Call Highlights: Strong Quvivic Sales and Strategic ...
GuruFocus News
Bullish
Idorsia Ltd (IDIA) Receives a Buy from Kepler Capital
TipRanks News
Bullish
Idorsia Earnings Call Signals Turnaround, Risks Linger
TipRanks News
Bullish
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
CH:IDIA
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.75 articles
News Sentiment
This Week100%
Sector Average67%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CH:IDIA’s Media Buzz Sentiment?
1 articles about CH:IDIA were published this week. In an average week, 1.75 articles are published.
    What is CH:IDIA’s weekly average amount of articles?
    In an average week, 1.75 articles about CH:IDIA are published.
      What is CH:IDIA’s News Sentiment?
      100% of articles about CH:IDIA were positive this week, compared to its sector average of 67%.
        Healthcare Stocks that are Trending in the News
        KHTRFKnight Therapeutics
        ABOSAcumen Pharmaceuticals
        KMTSKestra Medical Technologies Ltd.
        MISTMilestone Pharmaceuticals
        OVIDOvid Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week